Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like diabetes and even Ebola affecting more and more of the population, pharmaceutical companies are racing to find cures – further  advancing medicine and driving their stock prices up. Corporations like Pfizer (NYSE:PFE) and Gilead Sciences (NASDAQ:GILD) are leading the charge against disease but smaller companies such as Myland (NASDAQ:MYL) are interesting investments as well.

Recent Articles

Bear of the Day: AbbVie Inc Slide Shows No Quick End (ABBV)

AbbVie Inc is under pressure as the government reviews a patent and competitor Coherus waits in the wings More 

Is Pfizer Inc. Finally Safe To Buy Again? (PFE)

A first-quarter earnings and revenue beat has investors excited once again with formerly beat-down Pfizer Inc. Is now the time to buy PFE? More 

2 Drug Stocks To Buy For Safe Dividends And 20% Gains

With all the talk on the campaign trail about drug costs, it's safe to say the pharmaceutical industry is under siege. But these drug stocks are solid buys More 

Johnson & Johnson: How Healthy Is JNJ Stock?

Johnson & Johnson (JNJ) stock has long been a mainstay of many investors' healthcare holdings. But is JNJ's future still bright? More 

Pfizer Inc. Stock: A Good Buy While the Pharma Industry Is Down (PFE)

Between a planned merger with Allergan and a strong pipeline of drugs, PFE stock is a solid choice at a great price. More 

Bull of the Day: Momentum Powers Celgene Stock

Celgene's analyst conference was deceiving, as its estimated disappointed. But CELG stock is a pharmaceutical buy on it's forward momentum More 

Broker Darling: Pfizer Ranks As a Top 15 Analyst Pick (PFE)

A study of analyst recommendations shows that Pfizer is the #5 broker pick, on average, out of the 30 stocks making up the Dow Jones. More 

Why Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is one of the top broker picks in the Dow. More 

AZN: Why AstraZeneca’s Current Dip Is a Buying Opportunity

Astrazeneca has been investing aggressively in immuno-oncology, which will make AZN stock much more attractive in the long run. More 

The Big Winners in Teva’s Acquisition of Allergan Generics

Teva and Allergan benefit the most from the $40 billion deal, but prospects remain bright for Mylan, Perrigo and, indeed, the wider sector. More